US9044475 — Sublingual apomorphine
Formulation · Assigned to Cynapsus Therapeutics Inc · Expires 2030-06-11 · 4y remaining
What this patent protects
This patent protects sublingual formulations of apomorphine, specifically a mucoadhesive polymer film or strip, for treating Parkinson's disease, sexual dysfunction, and depressive disorders.
USPTO Abstract
The invention features sublingual formulations of apomorphine that is a mucoadhesive polymer film or a strip having a first portion including an acid addition salt of apomorphine and a second portion including a pH neutralizing agent, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders by administering sublingually the film or strip.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.